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Abstract
Background: Despite the popular use of vitamin supplements and several prospective cohort studies investigating
their effect on cancer incidence and cardiovascular disease (CVD), scientific data supporting their benefits remain
controversial. Inconsistent results may be partly explained by the fact that use of supplements is an inconsistent
behavior in individuals. We examined whether vitamin supplement use patterns affect cancer and CVD risk in a
population-based cohort study in Japan.
Methods: A total of 28,903 men and 33,726 women in the Japan Public Health Center-based Prospective Study cohort,
who answered questions about vitamin supplement use in the first survey from 1990-1994 and the second survey from
1995-1998, were categorized into four groups (never use, past use, recent use, and consistent use) and followed to the
end of 2006 for cancer and 2005 for CVD. Sex-specific hazard ratios (HRs) and 95% confidence intervals (95% CIs) were
used to describe the relative risks of cancer and CVD associated with vitamin supplement use.
Results: During follow-up, 4501 cancer and 1858 CVD cases were identified. Multivariate adjusted analysis revealed
no association of any pattern of vitamin supplement use with the risk of cancer and CVD in men. In women,
consistent use was associated with lower risk of CVD (HR 0.60, 95% CI 0.41-0.89), whereas past (HR 1.17, 95% CI
1.02-1.33) and recent use (HR 1.24, 95% CI 1.01-1.52) were associated with higher risk of cancer.
Conclusions: To our knowledge, this is the first prospective cohort study to examine simultaneously the
associations between vitamin supplement use patterns and risk of cancer and CVD. This prospective cohort study
demonstrated that vitamin supplement use has little effect on the risk of cancer or CVD in men. In women,
however, consistent vitamin supplement use might reduce the risk of CVD. Elevated risk of cancer associated with
past and recent use of vitamin supplements in women may be partly explained by preexisting diseases or
unhealthy background, but we could not totally control for this in our study.
Background
Despite the popular use of vitamin supplements, the
strong consumer belief is that they prevent chronic dis-
eases such as cancer and cardiovascular disease (CVD)
[1,2], but results from randomized controlled trials are
mixed [3-10]. Most randomized controlled trials show
little support of a preventive effect of vitamin
supplement use and even increased risk [6,7] for cancer
and CVD incidence and mortality, with some exceptions
[8-10]. However, data from randomized controlled trials
suffer from concerns about overreliance on secondary
rather than primary prevention, insufficient intervention
and follow-up periods, particularly regarding the inci-
dence of cancer, inappropriate supplement doses, and
unsuitable cohorts for testing the hypothesis. Therefore,
studies for the effects of long-term, low doses of several
agents in the general population are needed. Despite
several prospective cohort studies investigating their
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any medium, provided the original work is properly cited.effect on cancer incidence (all site [11,12], colorectal
[13-15], breast [16,17], lung [18,19], prostate [20-23],
non-Hodgkin lymphoma [24]), and CVD incidence
[11,25-29], scientific data supporting their benefits
remain controversial. Inconsistent results may be partly
explained by the fact that use of supplements is an
inconsistent behavior in individuals [13,30]. Individuals
with a favorable lifestyle and healthy diet are more likely
to use vitamin supplementation consistently [30]. Some
studies have found reduced risk for incidence and mor-
tality of cancer and CVD associated with a long dura-
tion of vitamin supplement use [13,14,27,28,31-34];
however, consistent use of vitamin supplements could
not be clearly determined by using a single time-point
survey at baseline.
It is also important to note that the use of vitamin
supplements is often associated with healthy lifestyle
factors or with specific health issues, such as hyperten-
sion and cancer, that may increase or decrease vitamin
supplement use [35,36]. In Japan, a few cross-sectional
studies reported that the prevalence of vitamin supple-
ment use was approximately 10% to 30% of the study
population and that vitamin supplement use was asso-
ciated with several factors broadly characterized by
health consciousness and conversely by poor health
[37-39]. However, all prospective studies have been con-
ducted in Western populations (United States
[11-15,17-29,31-34] and European countries [16,19,25]).
No data have been reported for prospective cohort stu-
dies in Asian general populations, although there are
some randomized clinical trials [8,40].
Therefore, we examined the association between vita-
min supplement use and the risk of cancer and CVD in
a population-based prospective cohort study in Japan.
Participants in this cohort reported vitamin supplement
use at two time points, which enabled us to examine the
impact of the pattern of use on the risk of cancer and
CVD.
Methods
The Japan Public Health Center (JPHC)-Based Prospec-
tive Study was started in 1990 for cohort I and in 1993-
1994 for cohort II. All subjects were Japanese inhabi-
tants registered at 11 public health center areas and
were aged 40-69 years at the time of their first survey.
Details of the study design have been described pre-
viously [41]. In the present study, the subjects from two
public health center areas (Katsushika in Tokyo prefec-
ture and Suita in Osaka prefecture) were excluded
because the incidence data for cancer or CVD were not
available and the selection of subjects differed from that
in other public health center areas. Of 116,896 people in
nine public health areas, 95,405 (82%) individuals
responded to the first survey. We excluded 1168 persons
who were not Japanese, who had died or moved out of a
study area, or who were lost to follow-up before the
starting point. This left 94,237 eligible subjects. In 1995
and 1998, the second survey was conducted; 79,809 sub-
jects replied (85%; 36,783 men and 43,026 women) and
were included in the present study. The institutional
review board of the National Cancer Center, Tokyo,
Japan, approved the study.
The status of vitamin supplement use was defined by
the responses in the two surveys and was classified into
the following four categories of use: (1) never, no vita-
min supplement use in either the first or second survey;
(2) past, vitamin supplement use only in the first survey;
(3) recent, vitamin supplement use only in the second
survey; and (4) consistent, vitamin supplement use in
both surveys. In the first survey, cohort I and cohort II
subjects were asked how frequently they used vitamin
supplements. Those who reported use on >1 day/week
were asked about the type of vitamin supplements. Use
of vitamin supplements in the first survey was defined
as subjects who used them at least 1 day/week. No
information was collected on brand name or duration of
vitamin supplement use. In the second survey for
cohorts I and II, general use of any vitamin supplements
more than once a week and use of specific vitamin sup-
plements were examined. The brand names of vitamin
supplements used were requested, and 81.7% provided
this information. We used re-categorized self-reported
categories of vitamin supplements based on the defini-
tion in the Women’s Healthy Eating and Living Study
[42] to improve sensitivity in identifying supplement use
[43]. Details of the assessment of self-reported vitamin
supplement use have been described previously, and use
of vitamin supplements in the second survey was
defined as subjects who used at least one type of vitamin
supplement ≥ 1 week for ≥ 1 year [37,43].
We followed subjects from the second survey until
December 31, 2006, for cancer and until December 31,
2005, for CVD. We identified changes in residence sta-
tus and survival annually through the residential registry
in each area or, for those who had moved out of the
area, by using the municipal office of the area to which
they had moved. Residency registration and death regis-
tration are required by the Basic Residential Register
Law and Family Registry Law, respectively, and the
registries are thought to be complete. During the fol-
low-up period, 8060 subjects (10.1%) died, 2106 (2.6%)
moved out of the study areas, and 249 persons (0.31%)
were lost to follow-up between the second survey and
December 31, 2006.
The occurrence of cancer was identified by active
patients’ notification from major local hospitals in the
study area, that is, the extraction of clinical information
from medical records into cohort-specific registration
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most of the patients with cancer or CVD (up to 80%) in
some areas, by physicians in the hospital or physicians
in the public health center [44], and from data linkage
with population-based cancer registries, with permission
from each of the local governments responsible for the
cancer registries. Cases of cancer were coded according
to the International Classification of Disease for Oncol-
ogy, third edition, of the World Health Organization
[45]. In our cancer registry system, the proportion of
cases for which information was available from death
certificates only was 4.4%. For the present analysis, the
earliest date of diagnosis was used in cases with multiple
cancer diagnoses at different times. Diagnosis of myo-
cardial infarction according to the criteria of the Moni-
toring Trends and Determinants of Cardiovascular
Disease (MONICA) project [46] and diagnosis of stroke
according to the criteria of the National Survey of
Stroke [47] were confirmed for all cases by computer
tomographic scan, magnetic resonance imaging, or both
as recorded in the medical record and reviewed by hos-
pital or public health center physicians in each regis-
tered major local hospital in each public health center
area [48,49]. CVD cases with a death certificate or by
self-report only, without confirmation by medical
records, were treated as non-CVD cases. CVD was
defined as myocardial infarction or stroke, whichever
occurred first. Among the 79,809 subjects, we confirmed
5932 cases of newly diagnosed cancer by December 31,
2006, and 3218 cases of CVD by December 31, 2005.
Participants with both cancer and CVD were included
in both analyses.
From the 79,809 respondents, we excluded subjects
w i t hah i s t o r yo fc a n c e ro rC V D( n = 5809) and those
who did not have information on their vitamin supple-
ment use in both surveys (n = 11,371). Subjects with a
history of cancer or CVD were defined as diagnosed
with cancer or CVD before the starting point or from
self-reports in the surveys. For the final analysis, 62,629
subjects (28,903 men and 33,726 women) remained,
including 4501 with cancer and 1858 with CVD. We
calculated person-years of follow-up for each subject
from the starting point to the date of diagnosis, date of
emigration from the study area, date of death, or end of
the follow-up (December 31, 2006 for the cancer analy-
sis and December 31, 2005 for the CVD analysis),
whichever came first. We censored subjects lost to fol-
low-up at the last confirmed date they were present in
the study area. A total of 597,281 person-years were
accrued for the cancer analysis and 547,983 for the
CVD analysis. Sex-specific hazard ratios (HRs) and 95%
confidence intervals (95% CIs) were used to describe the
relative risks of total cancer and CVD associated with
use of vitamin supplements. The Cox proportional
hazards model was used to control for potential con-
founding factors, which were either known or suspected
from previous studies as risk factors for cancer and
CVD. All covariates were based on information from
the second survey. We conducted the initial analyses by
adjusting for age at the starting point (5-year groups)
and study area (nine public health center areas). In the
multivariate model, we further adjusted for smoking sta-
tus (never, former, <20, 20-29, 30-39, and ≥ 40 pack-
years for men, and never, former, <20, and ≥ 20 pack-
years for women), alcohol consumption (none, <150,
150-299, 300-449, and ≥ 450 g ethanol/week for men,
and none, <150, and ≥ 150 g ethanol/week for women),
body mass index ([BMI] <19, 19-20.9, 21-22.9, 23-24.9,
25-26.9, 27-29.9, and ≥ 30 kg/m
2), occupation (farming,
forestry, and fishing; employee and professional; house-
wife; self-employed; unemployed; other occupations; and
combination [≥ 2 occupations across those groups]),
quartile of physical activity in metabolic equivalent task-
hours/day, total energy intake, energy-adjusted green
vegetable intake, current medication status (hyperten-
sion, hyperlipidemia, or diabetes mellitus), and screening
examination (blood pressure measurement, biochemical
examination, electrocardiogram, fundus examination,
chest radiograph, sputum cytology, gastric photofluoro-
graphy, gastrointestinal endoscopy, fecal occult blood
test, barium enema, or colonoscopy for men and
women, and mammography or Papanicolaou smear for
women), which were reported in a questionnaire in the
second survey. As for current medication status and
screening examination, if a subject replied “yes” to at
least one medication or examination, we regarded the
subject as using medication or taking the examination,
respectively. The second survey included a food-fre-
quency questionnaire consisting of 138 food items with
standard portions/units and nine frequency categories,
which were developed to estimate dietary intake [50]
and validated for estimations of various nutrients and
food groups [51-54]. A residual model was used for
energy adjustment of green vegetable consumption, vita-
min B2, vitamin B6, vitamin B12, folate, a-tocopherol,
vitamin C, and vitamin D intake reported in food-fre-
quency questionnaire [55]. Extreme values of BMI (<14
or ≥ 40 kg/m
2) and total energy intake (lower and upper
2.5 percentiles) were treated as missing values. Statistical
significance was assumed at P < 0.05. All statistical ana-
lyses were performed using SAS software, version 9.1
(SAS Institute, Cary, NC, USA).
Results
Of the participants included in this analysis, 49,060 sub-
jects (78.3%) reported no vitamin supplement use, 7833
subjects (12.5%) reported only past vitamin supplement
use (in the first survey), 2593 subjects (4.2%) reported
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vey), and 3143 subjects (5.0%) reported past and recent
vitamin supplement use. Among subjects who used vita-
min supplements and reported the brand name in the
second survey, the most common vitamin supplement
was B vitamins for men and women (multivitamin: 474
subjects [25.8%] and 566 subjects [19.6%]; antioxidants:
30 subjects [1.6%] and 126 subjects [4.4%]; vitamin A:
65 subjects [3.5%] and 144 subjects [5.0%]; B vitamins:
797 subjects [43.5%] and 883 subjects [30.6%]; vitamin
C: 299 subjects [16.3%] and 656 subjects [22.7%]; vita-
min E: 295 subjects [16.1%] and 843 subjects [29.2%];
other vitamins: 219 subjects [11.9%] and 443 subjects
[15.3%], respectively).
Table 1 shows the baseline characteristics of the study
subjects according to vitamin supplement use pattern in
men and women separately. Individuals with past use
and consistent use of vitamin supplements were signifi-
cantly older for both sexes. Men who had never used
supplements were thought to have lower health con-
sciousness due to higher proportions with a BMI ≥ 25
kg/m
2, a greater likelihood of being a smoker or regular
drinker, less information on their disease history
(angina, diabetes, colonic polyp, and hepatitis), fewer
screening examinations, and less consumption of soy
foods and fruits compared with other men. Significantly
higher proportions of men with consistent supplement
use took more medications (hyperlipidemia and dia-
b e t e s ) ,w e r em o r el i k e l yt oh a v ed i s e a s eh i s t o r i e s
(angina, diabetes, duodenal ulcer, colonic polyp, and
hepatitis), and may have higher health consciousness
suggested by lower BMI, less regular drinking, more
screening examinations, and higher consumption of
fruits. Men with past supplement use also had a signifi-
cantly higher proportion of antihypertensive medication
use. Men with recent use also tended to have a healthy
lifestyle and significantly lower proportions were smo-
kers or taking diabetic medication. Women who had
never used supplements were likely to have a healthier
lifestyle, with significantly lower proportions being smo-
kers or regular drinkers than other women. Women
with recent or consistent use were also basically health
conscious, having a lower BMI and a higher proportion
of screening examinations, despite there being a signifi-
cantly higher proportion of regular drinkers. Individuals
with consistent use also consumed significantly larger
amounts of fruits, folate, and vitamin C. They also
tended to have significantly higher proportions of medi-
cation use (hypertension and hyperlipidemia) and his-
tory of diseases such as gastr i ca n dc o l o n i cp o l y p st h a n
those who never used supplements. Women with recent
u s ew e r ea l s om o r el i k e l yt oh a v eah i s t o r yo fg a s t r i c
and colonic polyps, despite their younger age, and had a
significantly higher proportion of medication use except
for hypertension, hyperlipidemia, and diabetes. Women
with past use tended to have an unhealthy lifestyle,
including a higher BMI and a greater likelihood of
smoking and medication use (hypertension and
diabetes).
Associations of vitamin supplement use pattern and
total cancer and CVD risk in men and women are
shown separately in Table 2. In men, no significant
association was found between any pattern of vitamin
supplement use and the risk of total cancer and CVD
in age- and study area-adjusted and multivariate-
adjusted models. No significant association was found
between any specific vitamin supplement use in the
second survey and total cancer and CVD. For women,
however, a statistically significant increase in the risk
of total cancer occurrence was observed in those with
past and recent vitamin supplement use compared
with those who never used supplements; the HR of
developing cancer (95% CI) for past use and recent use
was 1.17 (1.02-1.33) and 1.24 (1.01-1.52), respectively.
When we performed separate analyses for major site-
specific cancers, the HR of recent use in women was
especially high for stomach cancer (HR 2.15, 95% CI
1.39-3.34). We also observed a nonsignificant but mod-
erately increased risk of liver and pancreatic cancer
with past supplement use in women (liver cancer: HR
1.61, 95% CI 0.95-2.74; pancreatic cancer: HR 1.67,
95% CI 0.94-2.97). When we estimated the HR after
excluding women diagnosed as having cancer within 5
years of baseline, similar trends were observed,
although the association for cancer with recent use
was not significant and with past use remained signifi-
cant. In the second survey, vitamin C supplements spe-
cifically and antioxidant supplementation, including
two or more of b-carotene, vitamin C, vitamin E, and
selenium [42], were significantly associated with an
increased risk of total cancer; compared with the sub-
jects with no vitamin supplement use, the HR and 95%
CI of vitamin C supplement and antioxidant supple-
ment use were 1.38 (1.03-1.87) and 1.83 (1.01-3.31),
respectively. In contrast, we observed a statistically sig-
nificant reduced risk for CVD with consistent vitamin
supplement use for women (HR 0.60, 95% CI 0.41-
0.89). When we performed separate analyses for coron-
ary heart disease, hemorrhagic stroke, or ischemic
brain infarction, decreased risk was observed for
ischemic brain infarction with statistical significance
with consistent use (coronary heart disease: HR 0.19,
95% CI 0.03-1.34; hemorrhagic stroke: HR 0.61, 95%
CI 0.29-1.31; ischemic brain infarction: HR 0.52, 95%
CI 0.28-0.98). HR estimates after excluding women
diagnosed with CVD within 5 years of baseline showed
a similar trend to estimates using all cases, although
they were not statistically significant.
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Page 4 of 10Table 1 Population characteristics according to supplement use categories, Japan Public Health Center-based
Prospective Study
Men (n = 28,903) Women (n = 33,726)
Never
use
Past
use
Recent
use
Consistent
use
P Never
use
Past
use
Recent
use
Consistent
use
P
No. (%) 23,535
(81.4)
3161
(10.9)
1026
(3.6)
1181 (4.1) 25,525
(75.7)
4672
(13.9)
1567
(4.6)
1962 (5.8)
Age in years (mean (SE*)) 55.7 (0.05) 57.9 (0.1) 57.1 (0.2) 58.2 (0.2) <.0001 56.1 (0.05) 57.9 (0.1) 56.7 (0.2) 57.8 (0.2) <.0001
Body mass index ≥ 25 kg/m
2 (%) 29.1 26.9 27.1 25.9 0.0049 29.0 31.0 26.3 23.6 <.0001
Smoking status
(%)
Former smoker 16.6 18.6 19.5 21.3 <.0001 0.7 1.2 1.7 1.4 <.0001
Current smoker 47.8 44.8 41.4 42.2 4.3 5.7 4.7 5.2
Regular drinker, ≥ 150 g ethanol/wk
(%)
50.5 46.1 46.8 45.5 <.0001 2.4 2.6 3.1 3.6 0.002
Mean MET*-
hours/d
(mean (SE)) 33.1 (0.05) 32.9 (0.1) 33.3 (0.2) 32.7 (0.2) 0.06 32.2 (0.04) 31.9
(0.09)
32.3 (0.2) 32.0 (0.1) 0.003
Medication (%) Hypertension 16.7 21.9 17.0 21.5 <.0001 17.8 24.4 18.1 20.0 <.0001
Hyperlipidemia 3.0 4.3 3.9 4.9 <.0001 6.0 7.8 7.5 9.3 <.0001
Diabetes 3.2 4.2 2.8 4.5 0.001 2.0 2.8 2.2 1.5 0.0005
Others 12.2 17.1 15.4 15.1 <.0001 10.9 13.1 16.3 15.9 <.0001
History (%) Angina 0.9 1.3 1.1 1.6 0.03 1.0 1.2 1.5 1.2 0.2
Diabetes 5.8 6.6 5.8 7.5 0.04 3.0 3.4 3.3 2.5 0.2
Gastric ulcer 5.0 5.4 5.0 4.9 0.8 2.1 2.3 2.6 2.9 0.07
Duodenal ulcer 2.5 2.0 1.9 3.5 0.02 1.2 1.2 1.4 1.3 0.9
Gastric polyp 2.2 2.3 2.6 3.3 0.09 2.6 2.4 3.3 3.7 0.004
Colonic polyp 4.1 4.3 4.9 5.8 0.03 1.8 1.7 2.0 3.3 <.0001
Hepatitis 1.7 1.9 2.3 3.2 0.0004 0.7 0.9 1.2 1.2 0.005
Screening examination (%) 83.3 84.0 87.0 88.0 <.0001 86.0 86.3 88.8 89.9 <.0001
Total energy intake (kcal/day) (mean
(SE))
2206 (4.2) 2200
(12.1)
2222
(20.4)
2228 (18.1) 0.5 1886 (3.6) 1879
(8.6)
1938
(14.5)
1925 (12.9) 0.0001
Energy-adjusted Salt intake (g/d) 12.2 (0.03) 12.3
(0.07)
12.4 (0.1) 12.3 (0.1) 0.5 12.0 (0.08) 11.9
(0.05)
11.7
(0.09)
11.7 (0.08) 0.5
food intake Soy food (g/d) 86 (0.5) 93 (1.6) 89 (2.3) 89 (1.8) 0.0001 86 (0.5) 94 (1.2) 86 (1.6) 89 (1.6) <.0001
(mean (SE)) Green vegetables
(g/d)
38 (0.2) 38 (0.6) 41 (1.2) 40 (1.0) 0.01 48 (0.2) 47 (0.6) 50 (1.1) 49 (0.8) 0.055
Fruits (g/d) 172 (1.0) 187 (2.9) 189 (4.8) 204 (4.7) <.0001 239 (1.1) 242 (2.5) 242 (4.0) 254 (3.9) 0.001
Fish (g/d) 91 (0.4) 91 (1.0) 92 (1.8) 92 (1.5) 0.7 87 (0.3) 86 (0.7) 86 (1.2) 86 (1.0) 0.4
Red meat (g/d) 52 (0.3) 51 (0.7) 53 (1.3) 51 (1.0) 0.5 46 (0.2) 48 (0.5) 45 (0.8) 46 (0.7) 0.0009
Energy-adjusted a-tocopherol (mg/
d)
6.6 (0.02) 6.8 (0.05) 7.1 (0.08) 7.1 (0.07) <.0001 7.3 (0.01) 7.5 (0.03) 7.5 (0.05) 7.6 (0.05) <.0001
nutrition intake Vitamin B1 (mg/d) 1.05
(0.003)
1.10
(0.008)
1.08
(0.01)
1.11 (0.01) <.0001 1.08
(0.002)
1.12
(0.006)
1.11
(0.009)
1.11 (0.008) <.0001
(mean (SE)) Vitamin B2 (mg/d) 1.41
(0.003)
1.45
(0.009)
1.50
(0.02)
1.52 (0.01) <.0001 1.43
(0.003)
1.46
(0.007)
1.51
(0.01)
1.54 (0.01) <.0001
Niacin (mg/d) 20.1 (0.04) 20.1 (0.1) 20.6 (0.2) 20.4 (0.1) 0.002 18.1 (0.03) 18.1
(0.07)
18.2 (0.1) 18.3 (0.09) 0.08
Vitamin B6 (mg/d) 1.56
(0.002)
1.58
(0.006)
1.60
(0.01)
1.60 (0.01) <.0001 1.46
(0.002)
1.47
(0.004)
1.48
(0.008)
1.49 (0.007) <.0001
Vitamin B12 (μ g/d) 9.1 (0.03) 9.2 (0.09) 9.3 (0.1) 9.4 (0.1) 0.02 8.6 (0.03) 8.7 (0.06) 8.7 (0.1) 8.6 (0.09) 0.2
Folate (μ g/d) 377 (0.9) 385 (2.7) 401 (4.9) 399 (4.1) <.0001 409 (0.9) 413 (2.2) 422 (3.8) 426 (3.1) <.0001
Pantothenic acid
(mg/d)
6.7 (0.01) 6.8 (0.03) 6.9 (0.05) 7.1 (0.05) <.0001 6.6 (0.008) 6.7 (0.02) 6.8 (0.03) 6.9 (0.03) <.0001
Vitamin C (mg/d) 118 (0.4) 122 (1.2) 128 (2.2) 130 (1.9) <.0001 151 (0.5) 149 (1.1) 154 (1.7) 158 (1.6) <.0001
Vitamin D (mg/d) 10.1 (0.04) 10.0 (0.1) 10.4 (0.2) 10.3 (0.2) 0.2 10.0 (0.04) 9.9 (0.09) 9.9 (0.1) 9.9 (0.1) 0.4
Never use, neither past nor recent use; Past use, past use but not recent use; Recent use, recent use but not past use; Consistent use, both past and recent use.
*SE, standard error; MET, metabolic equivalent task.
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unchanged when we further adjusted dietary vitamin B2,
B6,B 12, folate, a-tocopherol, vitamin C, and vitamin D
intake separately and simultaneously (data not shown).
Age, smoking status, alcohol intake, and dietary intake
of vitamin B2,B 6,B 12, folate, a-tocopherol, vitamin C,
and vitamin D did not significantly interact with any of
the above results (for all interactions, P > 0.5).
Discussion
In this prospective cohort study in an Asian population,
we found that vitamin supplement use has little effect
on the risk of total cancer or CVD in men. In women,
however, past and recent use of vitamin supplements
may be associated with higher risk of cancer, whereas
consistent use may be associated with lower risk of
CVD.
Several observational studies have examined the asso-
ciation between vitamin supplements and the risk of
cancer and CVD incidence, but results have varied
[11-29], partly because vitamin supplement use is an
inconsistent behavior in individuals [13,30]. In our
study, we found that only 4.1% of men and 5.8% of
women continued to use vitamin supplements from the
first to the second survey. Although some studies have
found reduced incidence and mortality risk of cancer
and CVD with a long duration of vitamin supplement
use [13,14,27,28,31-34], to our knowledge, only limited
d a t aa r ea v a i l a b l et oc l a r i f yt h ec o n s i s t e n c yo fv i t a m i n
supplement use over two surveys [13,31]. One prospec-
tive cohort study in the United States investigated con-
sistency for vitamin supplement use through two
surveys among 145,260 subjects, observing 797 incident
cases of colorectal cancer, and found that multivitamin
supplement use in the first survey and in both surveys
was associated with reduced risk of colorectal cancer,
whereas multivitamin supplement use in the second sur-
vey had no association with the disease [13]. Another
study, in which 3490 deaths were observed among
11,178 study subjects in the United States, found that
use of vitamin E supplements at two points within a
relatively short period (baseline and study inception 3
years earlier) was associated with reduced risk of coron-
ary heart disease mortality, whereas use at one point did
Table 2 Hazard ratios for total cancer and cardiovascular disease according to supplement use categories
Total Excluding cases within 5 years
Person-years No. of cases HR*1 (95% CI*) P HR2 (95% CI) P No. of cases HR2 (95% CI) P
Men
Total cancer
Never use 220,948 2152 1.00 (reference) 1.00 (reference) 1210 1.00 (reference)
Past use 28,863 324 0.98 (0.87-1.10) 0.8 0.98 (0.87-1.10) 0.8 167 0.95 (0.80-1.11) 0.5
Recent use 9603 102 1.00 (0.82-1.22) 0.97 1.01 (0.83-1.23) 0.9 59 1.05 (0.80-1.36) 0.7
Consistent use 10,863 139 1.11 (0.94-1.32) 0.2 1.10 (0.93-1.31) 0.3 75 1.13 (0.89-1.43) 0.3
Cardiovascular disease
Never use 203,013 934 1.00 (reference) 1.00 (reference) 490 1.00 (reference)
Past use 26,639 125 0.91 (0.75-1.09) 0.3 0.89 (0.73-1.07) 0.2 61 0.86 (0.66-1.12) 0.3
Recent use 8889 31 0.71 (0.50-1.02) 0.06 0.72 (0.51-1.04) 0.08 15 0.66 (0.39-1.10) 0.1
Consistent use 10,059 53 1.03 (0.78-1.36) 0.8 1.02 (0.77-1.35) 0.9 28 1.04 (0.71-1.53) 0.8
Women
Total cancer
Never use 248,659 1299 1.00 (reference) 1.00 (reference) 698 1.00 (reference)
Past use 44,237 287 1.19 (1.04-1.35) 0.01 1.17 (1.02-1.33) 0.02 157 1.21 (1.01-1.44) 0.04
Recent use 15,217 101 1.25 (1.02-1.53) 0.03 1.24 (1.01-1.52) 0.04 56 1.26 (0.96-1.66) 0.1
Consistent use 18,892 97 0.94 (0.76-1.16) 0.6 0.92 (0.75-1.13) 0.4 47 0.82 (0.61-1.11) 0.2
Cardiovascular disease
Never use 227,570 530 1.00 (reference) 1.00 (reference) 262 1.00 (reference)
Past use 40,586 116 1.11 (0.91-1.36) 0.3 1.08 (0.88-1.32) 0.5 63 1.24 (0.94-1.64) 0.1
Recent use 13,918 43 1.30 (0.95-1.77) 0.1 1.32 (0.97-1.81) 0.08 20 1.26 (0.80-1.99) 0.3
Consistent use 17,309 26 0.60 (0.40-0.89) 0.01 0.60 (0.41-0.89) 0.01 14 0.70 (0.41-1.21) 0.2
Never use, neither past nor recent use; Past use, past use but not recent use; Recent use, recent use but not past use; Consistent use, both past and recent use.
*HR, hazard ratio; CI, confidence interval.
HR1: Adjusted for age and public health center area.
HR2: Further adjusted for body mass index, smoking status, ethanol intake, occupation, daily total physical activity level, green vegetable intake, total energy
intake, medication, and screening examination.
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Page 6 of 10not show significant association in multivariate analysis
[31].
In the present study, the inverse associations for CVD,
especially for ischemic brain infarction, was observed
with consistent supplement use in women. It is known
that homocysteine may promote atherogenesis by dama-
ging the vascular matrix, increasing the proliferation of
endothelial cells, and facilitating oxidative injury to vas-
cular walls [56-58] and may be related to CVD [59,60].
Although several large trials of homocysteine-lowering
B-vitamin therapy have all failed to demonstrate a
reduction in coronary heart disease risk, some studies
have shown possible evidencef o rs t r o k e[ 9 , 1 0 ] .I th a s
also been reported that B vitamins are important enzy-
matic cofactors in the synthesis of methionine from
homocysteine and that a deficiency in any of them raises
homocysteine concentrations in the blood [61,62]. In the
present study, when we adjusted for several kinds of
dietary B vitamins (vitamin B2,v i t a m i nB 6, vitamin B12,
and folate), similar results were observed. Moreover, the
most common vitamin supplement in the second survey
was B vitamins in men and women in the present study
(36.1% and 25.0%, respectively, among vitamin supple-
ment users). Therefore, the inverse association between
the consistent use of vitamin supplement and risk of
CVD in women, especially ischemic brain infarction,
might be caused by supplementation with B vitamins.
Alternatively, past and recent use of vitamin supple-
ments was associated with higher risk of cancer in
women. Women with past use tended to have unhealthy
characteristics, such as a higher BMI, a greater likeli-
hood of smoking, and medication use (hypertension and
diabetes). Recent use in women may have been
prompted by symptoms of ill health because women
with recent use had a higher proportion of disease his-
tories (e.g., gastric and colonic polyps) despite their
younger age and had a significantly higher proportion of
medication use except for hypertension, hyperlipidemia,
and diabetes. Furthermore, the association of cancer
with recent use was not significant when we estimated
the HR after excluding women diagnosed as having can-
cer within 5 years of baseline, though that might be
partly caused by the decreased number of cases. Ele-
vated risk may be partly explained by characteristics of
t h ew o m e nt h a tw e r en o tm e a s u r e do rc o u l dn o tb e
controlled for in our study. Moreover, it might be partly
caused by a pro-oxidant effect of supplementation with
vitamin C [63-65], producing DNA damage and increas-
ing the risk of cancer, because use of vitamin C in the
second survey was associated with increased risk of total
cancer among women. Furthermore, high-dose antioxi-
dant supplementation might cause an increased risk of
cancer among a high-risk group; in addition, two large,
randomized clinical trials in which high doses of b-
carotene were used, the Beta-Carotene And Retinol Effi-
cacy Trial (CARET) in the United States and the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC)
trial in Finland, found that b-carotene, alone or in com-
bination with vitamin E or retinyl palmitate, increased
the incidence of lung cancers compared with placebo
among high-risk groups, such as heavy smokers and
those with a history of exposure to asbestos [6,7].
In the present study, vitamin supplement use was
associated with the risk of total cancer or CVD in
women but not in men. The characteristics of subjects
with each vitamin supplement pattern were different
between men and women, suggesting that these charac-
teristics and unmeasured or residual confounders might
cause the sex-based difference in results.
Our study has a potential limitation due to the differ-
ences in questionnaires regarding vitamin supplement
use between the first and second surveys, and these dif-
ferences might cause misclassification of vitamin supple-
ment use prevalence, which was lower in the second
survey than that in the first survey. Short-time vitamin
supplement use of <1 year was regarded as vitamin sup-
plement use in the first survey. In the second survey, re-
categorized self-reported categories of vitamin supple-
mentation were used to improve sensitivity in identify-
ing vitamin supplement use [43] and vitamin
supplement use was defined by vitamin supplements
being taken ≥ 1 time/week for a year or longer. Infor-
mation of duration was not available in the first survey.
In addition, the possibility of selection bias needs to be
considered when generalizing the present findings
because 15% of the eligible subjects did not reply in the
second survey. In our previous report, risks of mortality
for all causes, all cancers, and CVD were higher among
non-responders to the first survey compared with
responders and elevated risk for cancer was observed
only in the first 2 years of follow-up, whereas that for
stroke was relatively stable for the entire period [66].
The strength of this study was its prospective design,
which enabled us to avoid exposure recall bias. We
selected subjects from the general population, we kept
t h es a m p l es i z el a r g e ,t h er e s p o n s er a t ef o rt h es u r v e y s
was acceptable given its setting, and the loss to follow-
up was negligible. In addition, the registries of cancer,
stroke, and myocardial infarction were of sufficient qual-
ity to reduce the misclassification of outcomes. To our
knowledge, this is the first prospective cohort study to
examine associations between vitamin supplement use
pattern and risk of cancer and CVD incidence
simultaneously.
Conclusions
Allowing for the methodologic issues, our results from a
population-based prospective cohort study in Japan
Hara et al. BMC Public Health 2011, 11:540
http://www.biomedcentral.com/1471-2458/11/540
Page 7 of 10suggest that vitamin supplement use pattern has an
impact on the subsequent risk of total cancer and CVD
in women but not men. Elevated risk of cancer among
women who were past and recent users of vitamin sup-
plements may be partly explained by preexisting diseases
or unhealthy background, which could not be comple-
tely controlled for in our study. Although consistent use
of vitamin supplements for women might possibly
reduce the risk of CVD, further research with detailed
long-term data regarding components, doses, and pat-
terns of vitamin supplement use is needed to confirm
the generalizability of our findings.
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